Sign inJoin waitlistJoin the waitlist

Andrew Piper-Vallillo

Physician · Lahey Clinic

Credentials: · · · ·

History

Lahey Clinic
2021–Present

Hematology and Medical Oncology
Beth Israel Deaconess Medical Center
2018–2021
Internal Medicine
Massachusetts General Hospital
2015–2018
University of Massachusetts T.H. Chan School of Medicine
2011–2015

Research

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Annals of Oncology · 2021 · 260 citations
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
Journal of Clinical Oncology · 2020 · First of 3 authors · 158 citations
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
JTO Clinical and Research Reports · 2023 · 44 citations

Daniel Costa
10 papers
Deepa Rangachari
8 papers
Lecia Sequist
6 papers
ZP
Zofia Piotrowska
6 papers
Hollis Viray
5 papers · 1 as a fellow
LO
Leyre Zubiri Oteiza
4 papers
Heather Wakelee
3 papers
Joel Neal
3 papers
Julia Rotow
3 papers
Kartik Sehgal
3 papers · 2 as a fellow
KR
Kerry Reynolds
3 papers
PB
Poorva Bindal
3 papers · 3 as a fellow

Clinical trials

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2032
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2023–2031
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2017–2027